EA200000801A1 - Способ получения ингибиторов 5-липоксигеназы, включающих различные кольцевые гетероциклические системы - Google Patents

Способ получения ингибиторов 5-липоксигеназы, включающих различные кольцевые гетероциклические системы

Info

Publication number
EA200000801A1
EA200000801A1 EA200000801A EA200000801A EA200000801A1 EA 200000801 A1 EA200000801 A1 EA 200000801A1 EA 200000801 A EA200000801 A EA 200000801A EA 200000801 A EA200000801 A EA 200000801A EA 200000801 A1 EA200000801 A1 EA 200000801A1
Authority
EA
Eurasian Patent Office
Prior art keywords
obtaining
including various
inhibitors including
lipoxygenase inhibitors
heterocyclic systems
Prior art date
Application number
EA200000801A
Other languages
English (en)
Inventor
Тимоти Норрис
Джон Фрэнсис Лэмберт
Меган Элизабет Хнэтоу
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200000801A1 publication Critical patent/EA200000801A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Описан новый интермедиат, тетрагидро-4-[3-(4-фторфенил)тио]фенил-2H-пиран-4-карбоксамид формулытакже как и его использование в способе получения ингибиторов 5-липоксигеназы формулыкоторый заключается в образовании реакционной смеси, состоящей изэлектроно дефицитного моноциклического или бензоконденсированного бициклического N-гетероцикла, содержащего два атома азота, формулыв апротонном растворителе; в присутствии карбоната формулы: (M)-CO, где M - щелочной металл, элемент группы 1/Ia, выбранный из группы, состоящей из лития (Li), натрия (Na), калия (K), рубидия (Rb) и цезия (Cs), с последующим нагреванием указанной реакционной смеси в атмосфере азота; с получением целевого соединения вышеприведенной формулы.
EA200000801A 1999-08-31 2000-08-30 Способ получения ингибиторов 5-липоксигеназы, включающих различные кольцевые гетероциклические системы EA200000801A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15161599P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
EA200000801A1 true EA200000801A1 (ru) 2001-04-23

Family

ID=22539529

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000801A EA200000801A1 (ru) 1999-08-31 2000-08-30 Способ получения ингибиторов 5-липоксигеназы, включающих различные кольцевые гетероциклические системы

Country Status (33)

Country Link
US (1) US6346624B1 (ru)
EP (1) EP1081143A1 (ru)
JP (1) JP2001106682A (ru)
KR (1) KR20010050256A (ru)
CN (1) CN1286250A (ru)
AP (1) AP2000001910A0 (ru)
AU (1) AU5360300A (ru)
BG (1) BG104731A (ru)
BR (1) BR0003945A (ru)
CA (1) CA2317097A1 (ru)
CZ (1) CZ20003158A3 (ru)
EA (1) EA200000801A1 (ru)
EE (1) EE200000512A (ru)
GT (1) GT200000142A (ru)
HR (1) HRP20000564A2 (ru)
HU (1) HUP0003439A3 (ru)
ID (1) ID27129A (ru)
IL (1) IL138087A0 (ru)
IS (1) IS5603A (ru)
MA (1) MA26751A1 (ru)
NO (1) NO20004313L (ru)
NZ (1) NZ506632A (ru)
OA (1) OA11452A (ru)
PA (1) PA8499701A1 (ru)
PE (1) PE20010520A1 (ru)
PL (1) PL342281A1 (ru)
SG (1) SG87146A1 (ru)
SK (1) SK12872000A3 (ru)
SV (1) SV2002000159A (ru)
TN (1) TNSN00177A1 (ru)
TR (1) TR200002529A2 (ru)
UY (1) UY26314A1 (ru)
ZA (1) ZA200004435B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6669042B1 (en) * 2002-09-30 2003-12-30 Hewlett-Packard Development Company, L.P. Integrated positioning and locking device
EP1834953A1 (en) * 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063928A (en) * 1994-10-18 2000-05-16 Pfizer Inc 5-lipoxygenase inhibitors
US5883106A (en) * 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors
SK281577B6 (sk) 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
US6239285B1 (en) * 1998-02-06 2001-05-29 Pfizer Inc Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems

Also Published As

Publication number Publication date
TR200002529A2 (tr) 2001-04-20
PE20010520A1 (es) 2001-04-28
BG104731A (en) 2001-09-28
HUP0003439A3 (en) 2002-08-28
SV2002000159A (es) 2002-01-23
IL138087A0 (en) 2001-10-31
CA2317097A1 (en) 2001-02-28
HU0003439D0 (en) 2000-08-30
SG87146A1 (en) 2002-03-19
OA11452A (en) 2003-12-08
SK12872000A3 (sk) 2001-11-06
CZ20003158A3 (cs) 2001-09-12
PA8499701A1 (es) 2001-12-14
GT200000142A (es) 2002-02-19
NO20004313L (no) 2001-03-01
MA26751A1 (fr) 2004-12-20
CN1286250A (zh) 2001-03-07
JP2001106682A (ja) 2001-04-17
US6346624B1 (en) 2002-02-12
EP1081143A1 (en) 2001-03-07
TNSN00177A1 (fr) 2005-11-10
AP2000001910A0 (en) 2000-09-30
HRP20000564A2 (en) 2001-12-31
ID27129A (id) 2001-03-01
BR0003945A (pt) 2001-04-03
HUP0003439A2 (hu) 2001-08-28
IS5603A (is) 2001-03-01
EE200000512A (et) 2001-04-16
UY26314A1 (es) 2001-04-30
KR20010050256A (ko) 2001-06-15
PL342281A1 (en) 2001-03-12
ZA200004435B (en) 2002-02-28
NO20004313D0 (no) 2000-08-30
NZ506632A (en) 2002-02-01
AU5360300A (en) 2001-03-08

Similar Documents

Publication Publication Date Title
ES2106142T3 (es) Composiciones detergentes.
EA199900141A1 (ru) Цветообразующая композиция, содержащая реагент, включающий пирогаллольные структурные фрагменты, соль железа (ii) и органическую кислоту
BRPI0506462A (pt) método de combustão de concentrado de rejeito orgánico
EA200000801A1 (ru) Способ получения ингибиторов 5-липоксигеназы, включающих различные кольцевые гетероциклические системы
DE69220535T2 (de) Oberflächenaktive, von Sulfobernsteinsäureestern abgeleitete Verbindungen
RU2217434C1 (ru) Способ получения высокочистого цефподоксима проксетила
RU2002115289A (ru) Способ получения высокочистого цефподоксима проксетила
GB1453481A (en) Benzofuran derivatives process for their manufacture and their use as optical brighteners
JPS5392767A (en) Preparation of 2-phthalimidomethylindole derivatives
JPS5227791A (en) Synthesis of cephalosporins
Fesenko et al. Diastereoselective synthesis of 5-benzylthio-and 5-mercaptohexahydropyrimidin-2-ones
GB8311443D0 (en) Chemical compounds
ES8307235A1 (es) Un procedimiento para la preparacion de ranitidina.
ES467637A1 (es) Un nuevo procedimiento para preparar un compuesto de cefa- losporina
EP0994851B1 (en) Process for the preparation of 2-alkylthio benzoic acid derivatives
AR012141A1 (es) PROCESO PARA PREPARAR 1-ALQUILO-4-(2-CLORO-3-ALCOXIBENCENO), COMPUESTOS INTERMEDIARIOS DE APLICACIoN EN DICHO PROCESO Y PROCEDIMIENTO PARA PREPARAR DICHOS COMPUESTOS INTERMEDIARIOS
DK709188A (da) Fremgangsmaade til fremstilling af et pyrazolderivat
ES2031971T3 (es) Procedimiento para la obtencion de epoxidos fenilsubstituidos.
JPS532322A (en) Dephosphorizing agent for molten pig iron
Jiang et al. A simple and highly efficient preparation of structurally diverse aryl β‐diketoacids as hiv‐1 integrase inhibitors
DE3877455D1 (de) 5-halogen-6-amino-nikotin-saeurehalogenide, ihre herstellung und ihre verwendung.
DK379581A (da) Fremgangsmaade til fremstilling af acylderivater
Zhu et al. Reactions of N-sulfinylfluoroalkanesulfonylamides with alkene oxides
SU640663A3 (ru) Способ получени производных нитрохиназолинона
JPS5417399A (en) Thermally decomposing method for guypsum